are compounded glp 1 going away Hims & Hers stock falls 25% as FDA curtails GLP-1s FDA restricts non-approved compounded GLP-1
Description
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): A multicentre, randomised, open-label, parallel-group, phase 3 trial
In this review, we showed that GLP-1 receptor agonists can effectively change cognitive function, BMI and blood glucose levels in patients with AD

Fang M, Wang D, Coresh J, Selvin E

Clinical trials show average weight loss of 15-22% body weight over 68 weeks with consistent GLP-1 therapy
64 In contrast with prior anti-obesity medications, concerns about suicide intention have not been confirmed for GLP-1 RA therapy

As of September 2025, Medicare does not cover GLP-1 medications specifically for weight loss
